Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. (AIMT): 4 pipeline candidates · ~7 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.4 months
D/E 1.03 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Aimmune Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$266.6M
Quarterly Burn
$126.9M
Runway
7.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in Aimmune Therapeutics, Inc.'s pipeline?
Aimmune Therapeutics, Inc. (AIMT) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aimmune Therapeutics, Inc.'s lead drug candidate?
Aimmune Therapeutics, Inc.'s most advanced tracked candidate is aimab7195 (Preclinical) for Food allergies (adjunctive treatment).
What is Aimmune Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aimmune Therapeutics, Inc. has approximately 7.4 months of cash runway.
Who is the CEO of Aimmune Therapeutics, Inc.?
California April is the chief executive officer of Aimmune Therapeutics, Inc. (AIMT).
Get the full picture on Aimmune Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.